Biogen recorded declining sales for Spinraza in each of the four quarters of 2025, but the Massachusetts drugmaker sees ...
It's obvious that the company has a good shot at returning to growth.
That's the audience that the London Business School is targeting with a new one-year MBA program. Unlike a traditional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results